



Canadian Therapeutics Congress

Satellite Symposium

Disease Management Partnerships – Creating Health Solutions



Partner Organizations

- Nova Scotia Department of Health
- Heart and Stroke Foundation of Nova Scotia
- Cape Breton District Health Authority
- Capital District Health Authority
- Pfizer Canada, Inc
- QEII Foundation

A Novel approach to Cardiovascular Health by Optimizing Risk management



Why Anchor?

- Growing burden of risk factors and disease prevalence in cardiovascular and metabolic conditions
- Cardiovascular Health programs identify need for more “upstream” interventions
- National primary care renewal strategy -- community based teams with focus on prevention and enhanced **disease management**

A Novel approach to Cardiovascular Health by Optimizing Risk management



Disease Management

- Population based approach
 - supports the physician or practitioner/patient relationship and plan of care
 - emphasizes prevention of exacerbations and complications utilizing evidence-based practice guidelines and patient empowerment strategies
 - evaluates clinical, humanistic, and economic outcomes on an going basis with the goal of improving overall health

Disease Management Association of America

A Novel approach to Cardiovascular Health by Optimizing Risk management



Disease Management

Components:

- Population identification process
- Evidence-based practice guidelines
- Collaborative practice models to include physician and support-service providers
- Patient self-management education (may include primary prevention, behavior modification programs, and compliance/surveillance)
- Process and outcomes measurement, evaluation, and management
- Routine reporting/feedback loop (may include communication with patient, physician, health plan and ancillary providers, and practice profiling)

Disease Management Association of America

A Novel approach to Cardiovascular Health by Optimizing Risk management



Study Primary Objectives

- To improve management of global cardiovascular risk of patients within the primary care setting
- To increase patient compliance with lifestyle & pharmaceutical interventions aimed at decreasing global cardiovascular risk

A Novel approach to Cardiovascular Health by Optimizing Risk management



Study Design

- Case Control design with 1 year intervention
 - 1500 participants, 750 in each of two sites
 - Comparison cohort in 3rd primary care site
- Pre-post measurement:
 - Health Risk
 - Objective parameters (BP, Lipids, Glucose, etc.)
 - Readiness for change, motivation and barriers to change
 - Other parameters monitored include drug and service utilization to inform economic analysis

A Novel approach to Cardiovascular Health by Optimizing Risk management



Study Design

- Two participating Primary Care Practices:
 - Halifax – Alternate Funding
 - Sydney – Fee For Service
- Anchor intervention incorporates:
 - Health Risk Assessment
 - HRA Review
 - Individualized Goal Setting
 - Standardized follow up regime
 - Access to education, exercise and self management programs
 - Periodic review with family physician

A Novel approach to Cardiovascular Health by Optimizing Risk management



The Anchor Model...



A Novel approach to Cardiovascular Health by Optimizing Risk management




Health Risk Assessment

Calculates an individual's 10 year risk estimate of having a coronary event using the Framingham Heart Study model known as the **Framingham Score**

- Low Risk <10% 10 year risk estimate
- Moderate Risk 10-20% 10 year risk estimate
- High Risk > 20% 10 year risk estimate or **pre-existing Diabetes or any atherosclerotic disease**

Based on NCEP Guidelines

A Novel approach to Cardiovascular Health by Optimizing Risk management



A Novel approach to Cardiovascular Health by Optimizing Risk management



Behavioral Intervention

Assess Stage of Change for one or two self selected risk factors:

- Pre-contemplation
- Contemplation
- Preparation
- Action
- Maintenance

A Novel approach to Cardiovascular Health by Optimizing Risk management



Behavioral Intervention

- Motivators and strength of motivators
- Barriers and strength of barriers
- Goal selection:
 - Specific
 - Reasonable
 - Can be maintained over long term

A Novel approach to Cardiovascular Health by Optimizing Risk management



The Anchor Team

- Practice-based physician lead
- Nurse coordinator
- Dietician
- Consultants
 - Exercise specialist
 - Community pharmacist
- Investigators: Dr Blair O'Neil, Dr Jafna Cox, Dr Michael Vallis, Dr. Brendan Carr
- Project Manager

A Novel approach to Cardiovascular Health by Optimizing Risk management



ANCHOR Patients
As of May 5th, 2007

ANCHOR Patients by risk category (Baseline n=776 Males n=265 Females n=511)

	Low (<10%)	Moderate (10-20%)	High (>20%)
Females	27.8% (n=142)	37.4% (n=191)	34.8% (n=178)
Males	14.3% (n=38)	22.6% (n=60)	63.0% (n=167)
Combined	23.2% (n=180)	32.3% (n=251)	44.5% (n=345)

A Novel approach to Cardiovascular Health by Optimizing Risk management



ANCHOR Patients
As of May 5th, 2007

Patients with High Risk Default

Of the 776 patients recruited to the ANCHOR Study

206/776 or **26.5%**

default to high risk
without being able to change risk category because of established disease

A Novel approach to Cardiovascular Health by Optimizing Risk management



ANCHOR Patients
As of May 5th, 2007

ANCHOR Patients with Established Disease (Baseline n=776 Males n=265 Females n=511)

Disease	Gender	% of Participants by Gender
Diabetes	Female	17.6% (n=90)
	Male	17.0% (n=45)
	Total	17.4% (n=135)
Congestive Heart Failure	Female	0.6% (n=3)
	Male	1.1% (n=3)
	Total	0.8% (n=6)
Stroke	Female	0.8% (n=4)
	Male	3.0% (n=8)
	Total	1.5% (n=12)
Transient Ischemic Attack	Female	3.9% (n=20)
	Male	3.0% (n=8)
	Total	3.6% (n=28)
Coronary Heart Disease	Female	6.3% (n=32)
	Male	14.7% (n=39)
	Total	9.1% (n=71)

A Novel approach to Cardiovascular Health by Optimizing Risk management



ANCHOR Patients
As of May 5th, 2007

Patients with high risk default at 6 month HRA

Of the 234 patients who had a 6 month HRA,

81/234 or 34.6%

default to high risk
without being able to change risk category due to established disease

A Novel approach to Cardiovascular Health by Optimizing Risk management



Patients with Established Disease 6 Month HRA (n=234)

	# of Patients
Diabetes	55
Coronary Heart Disease	27
Stroke	5
Transient Ischemic Attack	14
Congestive Heart Failure	3
# Pts with 2 Diseases	17
# Pts with 3 Diseases	6
Total Patients	81



Risk Reduction Results



ANCHOR patients who have had a 6 month HRA and do not have established disease (n=153)

43/153 have reduced their risk **category** (28%)

54/153 have reduced their risk **score** (35%)



Original Risk with 6 Month Follow-up (n=234)



Patients with 6 Month HRA Follow-up (n=234)

Measurement	# Improved	# Worsened	# Same	Average Change
Weight (Kg)	143	59	32	-1.67 Kgs
BMI	158	65	11	-0.89
Systolic BP	116	109	9	+0.58
Diastolic BP	106	111	17	-0.41
HDL Chol	157	68	9	+0.11
LDL Chol	98	133	3	+0.13

Data based on HRA at Start, compared to 6 month follow-up HRA




Metabolic Syndrome Criteria


Three or more of the following Risk Factors:

- Waist Girth > 102 cm (Male) or 88 cm (Female)
- HDL < 1.0 mmol/L (Male) or 1.30mmol/L (Female)
- BP >= 130/85 /Blood Pressure Medication /Personal History
- Fasting Blood Glucose >= 5.6 mmol/L /Diabetic /Diabetic Medication
- Triglycerides >=1.69mmol/L


Metabolic Syndrome



Analysis of Drug Utilization



Lipid Lowering Drug Use




Patients with 6 Month HRA Follow-up

Initial Risk	% on LL Drugs Start	% on LL Drugs 6M	% on BP Drugs Start	% on BP Drugs 6M	% on Diabetic Drugs Start	% on Diabetic Drugs 6M	(n=234)
High	53%	57.7%	63.1%	68.5%	29.5%	31.5%	N=149
Mod	18.5%	21%	29.6%	37%	0%	1.2%	N=81
Low	75%	75%	50%	50%	0%	0%	N=4

Data based on HRA at Start, compared to 6 month Follow-up HRA

Project Organization



Operating Committee

- Principle Investigators
- Project Manager
- Medical and Research Specialists, Pfizer Canada



Steering Committee

- Department of Health
- Department of Health Promotion and Protection
- Participating Health Authorities
- Heart and Stroke Foundation of Nova Scotia
- Practice Leads
- Coordinators
- Principle Investigators
- Project Manager
- Medical and Research Specialists, Pfizer Canada

A Novel approach to Cardiovascular Health by Optimizing Risk management



Health Economics Working Group

- Research Health Economist, Department of Medicine, Dalhousie University
- Senior Health Economist, Department of Health
- Manager of Pharmacy Services, Department of Health
- Governmental Affairs Manager- Pfizer Canada
- Principle Investigator
- Project Manager

A Novel approach to Cardiovascular Health by Optimizing Risk management



Challenges and Lessons Learned

- Engagement of Fee for Service medical practice
- Health Risk Assessment technology → creating research platform
- Community applied research looks and feels very different than RCT's
- Importance of champions within each of the partner organizations
- Value of team building – learning skills to support behavioral change
- Collaboration is more than just different people all looking after the same patient
- Linking to existing community programs and services critical

A Novel approach to Cardiovascular Health by Optimizing Risk management



Thank you!

brendan.carr@cdha.nshealth.ca

www.anchorproject.ca

A Novel approach to Cardiovascular Health by Optimizing Risk management